The membrane tyrosine kinase receptor HER2 is implicated in breast cancer cell growth, differentiation, and angiogenesis, leading to aggressive disease biology and poor prognosis.5 Accurate biochemical assessment of HER2 with IHC and reflex ISH is paramount since initiation of anti-HER2 therapy improves oncologic outcomes. Here, ERBB2 is linked to breast cancer.